Fermentalg Reports Robust Sales Growth and Strategic Production Advancements

On May 14, 2024, at Vitafoods Europe 2024, Fermentalg, a pioneer in microalgae innovation, shared updates indicating significant sales growth and successful strategic advancements. In the first half of 2024, the company's sales are expected to surpass €6 million, effectively exceeding the annual target of €10 million set for the year. This growth follows a noteworthy 77% sales increase in the first quarter of 2024, highlighting Fermentalg's continued upward trajectory in the nutraceutical market.

In addition to financial success, Fermentalg revealed expansion within its DHA ORIGINS range at the Vitafoods event. The company has developed specialized products targeting pregnant women, young children, and pets, as well as sugar-free, flavored DHA gummies for family use. These products underscore Fermentalg’s strategic focus on innovation and market diversification.

The firm also announced a productive partnership with HuvePharma, marking a significant transition of production to the latter's facilities. This collaboration aims to establish a sustainable, fully localized production chain within the EU, enhancing industrial excellence and meeting stringent environmental goals. This move not only fortifies Fermentalg's supply chain but also positions it as a significant competitor in the omega-3 market, especially within the EU region.